Aptose Biosciences (APTO) shares gained 51% amid heavy trading after the firm said overnight a Nasdaq hearings panel approved its request for an extension to prove compliance with the exchange's listing requirements.
More than 289.8 million shares traded intraday compared with a daily average of about 1.2 million.
Humacyte (HUMA) said late Thursday the US Food and Drug Administration granted full approval for SYMVESS, a bioengineered human tissue designed to be universally implantable.
Shares rose 32% as intraday trading volume grew to more than 64.3 million from a daily average of about 3.11 million.
Taoping (TAOP) said Friday that the Nasdaq Stock Market confirmed the company was granted an additional 180 calendar days to comply with its minimum bid price requirement through June 16.
Shares increased 29%, with intraday trading volume at over 134.5 million compared with a daily average of about 739,000.
Price: 0.26, Change: +0.09, Percent Change: +51.41
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。